Previous close | 0.0400 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.1800 |
Strike | 142.00 |
Expiry date | 2024-05-31 |
Day's range | 0.0100 - 0.0100 |
Contract range | N/A |
Volume | |
Open interest | 11 |
RAHWAY, N.J., May 28, 2024--Merck Announces Third-Quarter 2024 Dividend
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
Merck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could continue, we...